文献速递慢病防控与筛查免疫规划

流感疫苗减少心力衰竭患者不良血管事件:一项多国随机双盲安慰剂对照试验

Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Glob Health · 2022-01-01

该试验在亚洲、中东和非洲10国30个中心纳入5129例心力衰竭患者,随机接受流感疫苗或安慰剂。全程观察的两个主要复合终点未达统计学显著,但在流感高峰期的预设分析中,疫苗组首次主要复合终点、全因死亡、心血管死亡和肺炎显著降低。

要点

  • 全程观察期主要复合终点无显著差异,但流感高峰期分析显示疫苗组事件显著降低
  • 疫苗组全因住院(HR 0.84)和肺炎(HR 0.58)显著减少
  • 作者认为结合既往试验和观察性研究,数据提示流感疫苗有临床获益

核心结论

  • 全程观察的两个主要复合终点未达统计学显著,但流感高峰期事件降低提示流感疫苗可能有临床获益。
  • 结合既往试验和观察性研究,集体数据提示获益。

研究设计与样本

  • 多国、实用、随机、双盲、安慰剂对照试验,在亚洲、中东和非洲10国30个中心进行。
  • 纳入5129例年龄≥18岁、NYHA心功能II、III或IV级的心力衰竭患者,1:1随机分配接受0.5 ml肌内注射灭活标准剂量流感疫苗或安慰剂(生理盐水),每年一次,最长3年。
  • 主要终点为首次事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中)和复发事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、心力衰竭住院)。
  • 在意向性治疗人群中每6个月评估结局。

主要发现

  • 首次主要复合终点在疫苗组380/2560(14.8%)vs 安慰剂组410/2569(16.0%),HR 0.93(95%CI 0.81-1.07),p=0.30。
  • 第二次主要复合终点在疫苗组754/2560(29.5%)vs 安慰剂组819/2569(31.9%),HR 0.92(95%CI 0.84-1.02),p=0.12。
  • 全因住院在疫苗组较安慰剂组显著降低(HR 0.84,95%CI 0.74-0.97,p=0.013)。
  • 肺炎在疫苗组较安慰剂组显著降低(HR 0.58,95%CI 0.42-0.80,p=0.0006)。
  • 全因死亡、心血管死亡、非致死性心肌梗死、非致死性卒中和心力衰竭住院在两组间无显著差异。

关键数值与推荐

  • 在流感高峰循环期的预设分析中,首次主要复合终点以及全因死亡、心血管死亡和肺炎在疫苗组显著低于安慰剂组。
  • 在流感高峰循环期的预设分析中,第二次主要复合终点以及非致死性心肌梗死、非致死性卒中、全因住院和心力衰竭住院在疫苗组未显著降低。

临床怎么用

  • 作者认为,鉴于肺炎明显减少、住院中度减少以及流感高峰期心血管事件和死亡减少,给予流感疫苗很可能有临床获益。
  • 作者认为结合既往试验和观察性研究,集体数据提示获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza increases the risk of cardiovascular events and deaths. We aimed to see whether influenza vaccination reduces death and vascular events in patients with heart failure. METHODS: We did a pragmatic, randomised, double-blind, placebo-controlled trial in 30 centres (mostly hospitals affliated with universities or a research institute) in ten countries in Asia, the Middle East, and Africa (7 in India, 4 in Philippines, 4 in Nigeria, 6 in China, 1 in Zambia, 2 in Mozambique, 3 in Saudi Arabia, 1 in Kenya, 1 in Uganda, and 1 in Zambia). Participants (aged ≥18 years; 52·1% female; not disaggregated by race or ethnicity) with heart failure (New York Heart Association class II, III, or IV) were randomly assigned (1:1) by a centralised web-based system with block randomisation stratified by site, to receive 0·5 ml intramuscularly once a year for up to 3 years of either inactivated standard dose influenza vaccine or placebo (saline). We excluded people who had received influenza vaccine in 2 of the previous 3 years, and those likely to require valve repair or replacement. Those who administered assigned treatments were not masked and had no further role in the study. Investigators, study coordinators, outcome adjudicators, and participants were masked to group assignment. The first of two co-primary outcomes was a first-event composite for cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, and the second was a recurrent-events composite for cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure. Outcomes were assessed every 6 months in the intention-to-treat population. Secondary outcomes were all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, all-cause hospitalisation, hospitalisation for heart failure, and pneumonia, both overall and during periods of peak influenza exposure. This study is registered with ClinicalTrials.gov, NCT02762851. FINDINGS: Between June 2, 2015, and Nov 21, 2021, we enrolled 5129 participants and randomly assigned (1:1) 2560 (50·0%) to influenza vaccine and 2569 (50·0%) to placebo. The first co-primary outcome occurred in 380 (14·8%) of 2560 participants in the vaccine group and 410 (16·0%) of 2569 participants in the placebo group (hazard ratio [HR] 0·93 [95% CI 0·81-1·07]; p=0·30). The second co-primary outcome occurred in 754 (29·5%) of 2560 participants in the vaccine group and 819 (31·9%) of 2569 participants in the placebo group; HR 0·92 [95% CI 0·84-1·02]; p=0·12). The secondary outcomes of all-cause hospitalisations (HR 0·84 [95% CI 0·74-0·97]; p=0·013) and pneumonia (HR 0·58 [0·42-0·80]; p=0·0006) were significantly reduced in the vaccine group compared with in the placebo group but there was no significant difference between groups for all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure. In a prespecified analysis, in which events were limited to periods of peak influenza circulation, the first co-primary outcome, and the secondary outcomes of all-cause death, cardiovasular death, and pneumonia were significantly lower in the vaccinated group than in the placebo group, whereas the second co-primary outcome and the secondary outcomes of non-fatal myocardial infarction, non-fatal stroke, all-cause hospitalisation, and hospitalisation for heart failure were not significantly lower. INTERPRETATION: Although the prespecified co-primary outcomes during the entire period of observation were not statistically significant, the reduction during the peak influenza circulating period suggests that there is likely to be a clinical benefit of giving influenza vaccine, given the clear reduction in pneumonia, a moderate reduction in hospitalisations, and a reduction in cardiovascular events and deaths during periods of peak circulation of influenza. Taken in conjunction with previous trials and the observational studies, the collective data suggest benefit. FUNDING: UK Joint Global Health Trials Scheme and Canadian Institutes for Health Research Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Loeb M, Roy A, Dokainish H, et al. Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2022. PMID: 36400089. doi:10.1016/S2214-109X(22)00432-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。